Intranasal Ketamine Versus Intramuscular Ketamine for Procedural Sedation in Pediatric Patients
Intranasal Ketamine Versus Intramuscular Ketamine for Procedural Sedation: A Prospective Randomized, Double-blinded, Placebo Controlled Study
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Iowa
-
Iowa City, Iowa, United States, 52242
- University of Iowa Hospitals and Clinics
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- pediatric patients age 2 to 17 years old
- have a laceration of 4 cm on the face or 7 cm on the remainder of the body
- Require procedural sedation to repair the laceration
Exclusion Criteria:
- Patients with abnormal nasal physiology which would not allow for adequate medication delivery
- Unable to have a guardian present to consent on their behalf
- Allergy to ketamine
- Significant cardiac history (myocardial ischemia, heart failure, arrhythmias)
- Presenting with a head injury associated with possible intracranial hypertension
- Pregnancy
- Lacerations that require repair from a consult service
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Intranasal Ketamine
|
Intranasal Ketamine (100 mg/mL)
Intramuscular Ketamine
|
|
Active Comparator: Intramuscular Ketamine
|
Intranasal Ketamine (100 mg/mL)
Intramuscular Ketamine
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Onset of Sedation
Time Frame: Every 60 seconds through study completion
|
Minutes it takes until the patient is cooperative enough for the procedure
|
Every 60 seconds through study completion
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Brett Faine, Pharm.D., University of Iowa
- Principal Investigator: Andrew Nugent, MD, University of Iowa
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Central Nervous System Depressants
- Peripheral Nervous System Agents
- Analgesics
- Sensory System Agents
- Anesthetics, Dissociative
- Anesthetics, Intravenous
- Anesthetics, General
- Anesthetics
- Excitatory Amino Acid Antagonists
- Excitatory Amino Acid Agents
- Ketamine
Other Study ID Numbers
Other Study ID Numbers
- 201006786
- University of Iowa
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.